Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-01-04
2005-01-04
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S003100, C514S365000, C514S369000, C514S451000, C514S457000, C514S866000
Reexamination Certificate
active
06838442
ABSTRACT:
Combination therapy comprising RXR modulators and glucose reabsorption inhibitors useful for the treatment of diabetes and Syndrome X are disclosed.
REFERENCES:
patent: 5424406 (1995-06-01), Tsujihara et al.
patent: 5731292 (1998-03-01), Tsujihara et al.
patent: 5731299 (1998-03-01), Ebetino et al.
patent: 5767094 (1998-06-01), Tsujihara et al.
patent: 5830873 (1998-11-01), Tsujihara et al.
patent: 6048842 (2000-04-01), Tsujihara et al.
patent: 6153632 (2000-11-01), Rieveley
patent: 6515003 (2003-02-01), Pfahl et al.
patent: 1 213 296 (2002-08-01), None
patent: WO 9710819 (1997-03-01), None
patent: WO 0061127 (2000-10-01), None
patent: WO 0114372 (2001-03-01), None
patent: WO 0117513 (2001-03-01), None
patent: WO 0174834 (2001-10-01), None
patent: WO 0174835 (2001-10-01), None
Windholz et al., The Merck Index, Tenth Edition (1983) pp. 723 and 724, abstract No. 4866.*
Consoli, Agostino, MD. “Role of Liver in Pathophysiology of NIDDM”, Diabetes Care, vol. 15, No. 3, Mar. 1992 pp 430-441.
Day, C. “Thiazolidinedlones: a new clas of antidiabetic drugs”, Diabetic Medicine, vol. 16, No. 3, 1999, pp. 179-192.
Deetjen, Peter et al. “Renal Handling of D-Glucose and Other Sugars”, 1995 pp. 90-94.
Evans, Alison J. and Krentz, Andrew J., “Recent Developments and Emerging Therapies for Type 2 Diabetes Mellitus”, Drugs R&D 2:Aug. 2, 1999, pp. 75-94.
Freychet, P., “Pancreatic Hormones”. In Hormones from molecules to disease. Kelly, P.A. Baulieu, E.E., eds., Routledge, Chapman and Hall, New York, NY pp. 491-532.
Gerich, J.E., “Role of Liver and Muscle in Type II Diabetes”, Horm. Metab. Res., vol. 26, 1992, pp. 18-21.
Groop, L.C. “Drug treatment of non-insulin-dependent diabetes mellitus” Textbook of Diabetes, Pickup, J.C., Williams, G. eds., Blackwell Science Oxford, UK, 1-18, 1997, pp. 38.1-38.18.
Lee, Wen-Sen et al., “The High Affinity Na+/Glucose Cotransporter”, The Journal of Biological Chemistry, vol. 269, No. 16, Apr. 22, 1994, pp. 12032-12039.
Link, J. T. and Sorensen, Bryan K., “A method for preparing C-glycosides related to phlorizin”, Tetrahedron Letters 41, 2000, pp 9213-9217.
Mackenzie, Bryan et al. “SAAT1 Is a Low Affinity Na +/Glucose Cotransporter and Not an Amino Acid Transporter”, The Journal of Bilogical Chemistry, vol. 269, No. 36, Issue of Sep. 9, 1994, pp 22488-22491.
Oku, Akira et al., “T-1095, an Inhibitor of Renal Na=-Glucose Cotransporters, May Provide a Novel Approach to Treating Diabetes”, Diabetes, vol. 48, Sep. 1999, pp 1794-1800.
Rossetti, Luciano et al., “Correction of Hyperglycemia with Phlorizin Normalizes Tissue Sensitivity to Insulin in Diabetic Rats”, J. Clin. Invest., vol. 79, May 1987, pp. 1510-1515.
Rosetti, Luciano et al., “Glucose Toxicity”, Diabetes Care, vol. 13, No. 6, Jun. 1990 pp 610-630.
Silverman, Mel and Turner James, R., “Glucose transport in the renal proximal tubule”, Chapter 43, Membrane Biology Group, Dept. of Medicine, University of Toronto, Toronto, Ontario, Canada, 1992 pp 2017-2038.
Unger, R.H. and Grundy, S., “Hyperglycaemia as an Inducer as well as a consequence of Impaired islet cell function and insulin resistance: implications for the management of diabetes”, Diabetologia, vol. 28, 1985 pp. 119-121.
You, Guofeng et al., “Molecular Characteristics of Na+-coupled Glucose Transporters in Adult and Embryonic Rat Kidney”, The Journal of Biological Chemistry, vol. 270, No. 49, Issue of Dec. 8, 1995, pp 29365-29371.
PCT International Search Report PCT/US02/10542 dated Jul. 31, 2002.
Buse, J.B., Gumbiner, B. Mathias, N.P.et al. “Troglitazone use in insulin-treated type 2 diabetic patients”; The Troglitazone Insulin study group, Diabetes Care 21: pp. 1455-1461 (1998).
Cha, B.S. et al.; Peroxisome Proliferator-Activated Receptor (PPAR) and Retinoid X Receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle.: Diabetoglogia 44: pp. 444-452 (2001).
Mukherjee, R., Davies, P.J.A., Crombie, D.L., Dischoff, E.D. Cesario, R.M. et al.; “Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists”; Nature 386: pp. 407-410 (1997).
Nestler, J.E., Jakubowicz, D.J., Reamer, P. et al. “Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome”; N. Engl. J. Med. 340: pp. 1314-1320 (1999).
Schwartz, S., Raskin, P., Fonseca, V., and Graveline, J.F. “Effect of troglitazone in insulin-treated patients with type 2 diabetes”; N. Engl. J. Med. 338: pp. 861-866 (1998).
UK Prospective Diabetes Study Group, “Intensive blood-glucose control with sulfphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes”; Lancet 352: pp. 837-853 (1998).
UK Prospective Diabetes Study Group, “Effect of Intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes”, Lancet 352: pp. 854-865 (1998).
Bussolari Jacqueline C.
Chen Xiaoli
Conway Bruce R.
Demarest Keith T.
Ross Hamish N. M.
Ortho-McNeil Pharmaceutical , Inc.
Weddington Kevin E.
LandOfFree
Combination therapy comprising glucose reabsorption... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy comprising glucose reabsorption..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy comprising glucose reabsorption... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3399563